115690-05-6

Upstream product

• 115690-00-1 ethyl (4R,5R)-4-benzyloxy-2-ethoxycarbonyl-5,6-isopropylidenedioxyhexanoate 
• 115690-02-3 ethyl (4R,5R)-4-benzyloxy-5,6-isopropylidenedioxyhexanoate 
• 115689-97-9 1-methanesulfonyloxy-2-O-benzyl-3,4-O-isopropylidene-D-threitol 
• 115887-36-0 (4R)-4-(benzyloxy)-4-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)butan-1-ol 
• 115689-96-8 (2R,3S)-3-O-benzyl-4-iodo-1,2-O-isopropylidenebutane-1,2,3-triol 
• 84379-54-4 (R)-2-(benzyloxy)-2-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol 
• 115690-04-5 (2R,3R)-3-benzyloxy-6-(tert-butyldiphenylsiloxy)-1,2-isopropylidenedioxyhexane 

Downstream Products

• 126840-42-4 (S)-3,3,3-Trifluoro-2-methoxy-2-phenyl-propionic acid (2S,3R)-2-trityloxymethyl-tetrahydro-pyran-3-yl ester 
• 115690-11-4 (2S,3R)-2-triphenylmethoxymethyltetrahydropyran-3-yl N-heptadecylcarbamate 
• 115690-07-8 (2R,3R)-3-benzyloxy-6-hydroxy-1-triphenylmethoxy-2-hexyl methanesulfonate 
• 115690-09-0 (2S,3R)-3-benzyloxy-2-triphenylmethoxymethyltetrahydropyran 
• 115690-10-3 (2S,3R)-2-triphenylmethoxymethyltetrahydropyran-3-ol 
• 126840-43-5 (2S,3R)-3-benzyloxy-2-methoxymethoxymethyltetrahydropyran 
• 119116-56-2 <(2S,3R)-3-benzyloxytetrahydropyran-2-yl>methanol 
• 115690-08-9 Methanesulfonic acid (1R,2R)-2-benzyloxy-5-(tert-butyl-diphenyl-silanyloxy)-1-trityloxymethyl-pentyl ester 
• 115690-06-7 (2R,3R)-3-benzyloxy-6-(tert-butyldiphenylsiloxy)-1-triphenylmethoxyhexan-2-ol 

Relevant academic research and scientific papers

A stereoselective synthesis of medium-sized cyclic ethers by the intramolecular cyclization of linear hydroxyalkyl-propargylic alcohols assisted by Co2(CO)8

A highly efficient, mild and general cyclization reaction of hydroxy exo-(propargyl)Co2(CO)6 cations leading to medium-sized (6 to 9 membered) cyclic ethers is described. The reaction is highly stereoselective when defined stereocenters are encountered in the linear precursor, providing a way to obtain fused cyclic ethers in their enantiomeric forms.

Cyclic ether derivatives and their use

Compounds of formula (I): STR1 (wherein: l is 2-4; A and B are oxygen or sulfur; one of R1 and R2 represents a long chain alkyl, alkylcarbamoyl or aliphatic acyl group and the other of R1 and R2 represents a group of formula (III) or (IIf): STR2 in which E represents a single bond, a bivalent heterocyclic group or a group of formula --CO--, --COO-- or --CONR6 --, where R6 is hydrogen or an imino-protecting group; m is 0-3; n is 0-10; q is 0 or 1; R4 is optionally protected hydroxy, mercapto group or carboxy; Q is an amino or nitrogen-containing heterocyclic group; Rf4 Rf5 and Rf6 are independently selected from the group consisting of hydrogen atoms and C1 -C6 alkyl groups, or Rf4 and Rf5 or Rf4, Rf5 and Rf6, together with the nitrogen atom to which they are attached, form a heterocyclic ring) are PAF antagonists which may be used to treat asthma, hypotension, inflammation and shock. They may be prepared by reacting the corresponding compound having a haloalkyl phosphate ester or alkylenephosphate ester group in place of the ammonioalkyl phosphate ester group with an appropriate amine.